Cargando…

Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms

BACKGROUND: Small molecule ONC201 is an investigational anti-tumor agent that upregulates intra-tumoral TRAIL expression and the integrated stress response pathway. A Phase I clinical trial using ONC201 therapy in advanced cancer patients has been completed and the drug has progressed into Phase II...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wagner, Jessica, Kline, C. Leah, Zhou, Lanlan, Khazak, Vladimir, El-Deiry, Wafik S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778752/ https://www.ncbi.nlm.nih.gov/pubmed/29357916 http://dx.doi.org/10.1186/s13046-018-0671-0

Ejemplares similares

Role of Dopamine Receptors in the Anticancer Activity of ONC201()()
por: Kline, Christina Leah B., et al.
Publicado: (2017)

Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo
por: Ray, Jocelyn E., et al.
Publicado: (2021)

The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity
por: Wagner, Jessica, et al.
Publicado: (2015)

Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo
por: Jhaveri, Aakash V., et al.
Publicado: (2021)

Discovery and clinical introduction of first-in-class imipridone ONC201
por: Allen, Joshua E., et al.
Publicado: (2016)

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic
por: Ralff, Marie D., et al.
Publicado: (2020)

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201
por: Allen, Joshua E., et al.
Publicado: (2021)

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
por: Prabhu, Varun Vijay, et al.
Publicado: (2020)

First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent
por: Allen, Joshua E., et al.
Publicado: (2015)

Correction: First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent
por: Allen, Joshua E., et al.
Publicado: (2016)

ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
por: Ferrarini, Isacco, et al.
Publicado: (2021)

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors
por: Prabhu, Varun V., et al.
Publicado: (2017)

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway
por: Allen, Joshua E, et al.
Publicado: (2015)

EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG
por: Zhang, Yiqun, et al.
Publicado: (2021)

DIPG-57. TRANSCRIPTOMIC AND PROTEOMIC ANALYSES OF DIPG RESPONSE TO ONC201
por: Sridharan, Sreepradha, et al.
Publicado: (2020)

Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
por: Kline, Christina Leah B., et al.
Publicado: (2013)

HGG-36. ONC201 TARGETING IN DIPG
por: Abuarqoub, Alqassem, et al.
Publicado: (2021)

SYST-07 WINDOW-OF-OPPORTUNITY STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND THALAMIC GLIOMA
por: Odia, Yazmin, et al.
Publicado: (2022)

Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy
por: Gardner, Sharon L, et al.
Publicado: (2022)

Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor()
por: Hayes-Jordan, Andrea A., et al.
Publicado: (2018)

HGG-44. REVEALING VULNERABILITIES IN DIPG THROUGH ONC201
por: Stafford, James, et al.
Publicado: (2021)

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
por: Stein, Mark N., et al.
Publicado: (2019)

DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG
por: Gardner, Sharon, et al.
Publicado: (2020)

TIC10/ONC201: a bend in the road to clinical development
por: Greer, Yoshimi Endo, et al.
Publicado: (2015)

ONC201 kills breast cancer cells in vitro by targeting mitochondria
por: Greer, Yoshimi Endo, et al.
Publicado: (2018)

Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells
por: Zhang, Shengliang, et al.
Publicado: (2022)

Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients
por: Leaf, Sofia, et al.
Publicado: (2021)

Microarray analysis reveals ONC201 mediated differential mechanisms of CHOP gene regulation in metastatic and nonmetastatic colorectal cancer cells
por: Al Madhoun, Ashraf, et al.
Publicado: (2021)

Raw Lacquer Extract from Toxicodendron vernicifluum in Combination with ONC201 Enhances the Inhibitory Effects on Colorectal Cancer Cell Activity
por: Jin, Zhezhu, et al.
Publicado: (2023)

Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers
por: Carlsen, Lindsey, et al.
Publicado: (2022)

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs
por: Huntington, Kelsey E., et al.
Publicado: (2021)

ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells
por: Yuan, Xun, et al.
Publicado: (2017)

Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues
por: Graves, Paul R., et al.
Publicado: (2019)

Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells
por: Amoroso, Francesca, et al.
Publicado: (2021)

Molecular Mechanisms Involved in the Chemical Instability of ONC201 and Methods to Counter Its Degradation in Solution
por: Annereau, Maxime, et al.
Publicado: (2023)

A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins
por: El-Soussi, Sarra, et al.
Publicado: (2021)

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma
por: Tu, Yong-sheng, et al.
Publicado: (2017)

DIPG-32. AKT SIGNALING DRIVES RESISTANCE TO ONC201 IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Jackson, Evangeline R, et al.
Publicado: (2020)

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
por: Lim, Bora, et al.
Publicado: (2021)

MEDB-46. ONC201 affects Group 3 Medulloblastoma growth by impairing cancer stem cells
por: Abballe, Luana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_polfkrphob76jchalstd6gm063